Financings

Aclarion (ACON) sells $10,359,982 of stock and pre-funded warrants

ACON

Aclarion, Inc. (Nasdaq: ACON) agreed on January 8, 2026 to sell 200,000 shares and pre-funded warrants for 1,800,000 shares in a registered direct offering with Dawson James Securities, Inc.

Investor Chat

Scorecard

ACONEquity
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-08
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-08
Mixed record
Investment Attractiveness: 5.3/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

Equity: common stock

Warrant coverage0%

By the aibio.space news desk

A historic city courthouse
A historic city courthouse. Photo: Daderot, CC0, via Wikimedia Commons. The picture shows the field, not the companies named.

Aclarion, Inc. (Nasdaq: ACON) agreed on January 8, 2026 to sell 200,000 shares of common stock and pre-funded warrants to buy up to 1,800,000 more shares, in a registered direct offering. The company disclosed the purchase agreement in a Form 8-K filed on January 9, 2026. The company expects gross proceeds of $10,359,982, before fees and expenses. The offering was made under a shelf registration statement on Form S-3 and a prospectus supplement filed the same day.

Why is this important: The offering adds shares and pre-funded warrants that can be exercised into common stock at a nominal price, so the share count can rise. The price was $5.18 per share, against a last reported sale price of $5.75 on January 7, 2026. For shareholders, the deal raises cash that the company says it will use for clinical evidence and product work. For the placement agent, the fee is 6% of gross proceeds, plus expenses.

Brent Ness, the chief executive, is the company's chief operating decision maker in its financial statements. In our view, the company has raised money at a steady pace. Its Nociscan report business is growing, and the filings show repeated share sales. We think the record supports a plain conclusion: the company is financing its growth with dilution, and the market has to accept that cost.

The terms of the offering

The purchase agreement, dated January 8, 2026, covers two items. The first is 200,000 shares of common stock at $5.18 per share, or pre-funded warrants in lieu of those shares. The second is pre-funded warrants for up to 1,800,000 shares. The pre-funded warrants can be exercised at $0.00001 per share at any time, subject to a 4.99% or 9.99% beneficial ownership limit that the holder can change on 61 days' notice.

The prospectus supplement puts the offering total at $10,359,982, with placement agent fees of $621,600 and proceeds of $9,738,382 before expenses. Dawson James Securities, Inc. is the exclusive placement agent, and the company has agreed to pay it a cash fee of 6% of gross proceeds and to reimburse certain expenses. The 8-K says the legal opinion on the shares was given by Carroll Legal LLC.

The company says it intends to use the net proceeds for market development and clinical evidence, for The Clarity Trial, for product development and quality, for general and administrative support, and for other general corporate purposes. The 8-K does not give a split among those uses.

The business behind the offering

Aclarion's revenue comes from Nociscan reports, which it delivers to clients for a fee. The third-quarter report for the period ended September 30, 2025 says revenue increased as volume of Nociscan reports grew in the United Kingdom, after local coverage decisions there.

The Clarity Trial is the company's post-market clinical study. The third-quarter report says the company started the trial and enrolled its first patient in June 2025, and that research and development expenses are expected to rise as enrollment expands. The filings name no ClinicalTrials.gov registration for the Clarity Trial, so this article cites none.

As of September 30, 2025, the company reported cash and cash equivalents of $11,366,336. The third-quarter report said that the company raised an additional $2.5 million in October 2025 in a registered direct public offering. The January 2026 offering is a separate transaction and raises a further amount that is not yet reflected in the September 30, 2025 figures.

What comes next

The closing was expected on or about January 9, 2026, subject to customary conditions. The filings set no later date for a new financing and name no other planned transaction. The next scheduled filings are the company's annual report and the quarterly reports that follow it.

The offering is described in the Form 8-K filed January 9, 2026. The prospectus supplement with the offering table is in the Form 424B5 filed January 9, 2026, and the most recent interim figures before the offering are in the Form 10-Q for the quarter ended September 30, 2025.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.